Navigation Links
DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective
Date:10/29/2008

CUPERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the previously announced development and license agreement with Alpharma Ireland Limited, an affiliate of Alpharma Inc. (NYSE: ALO), granting such party the exclusive worldwide rights to develop and commercialize ELADUR(TM), DURECT's investigational transdermal bupivacaine patch, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and has become effective.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/LAW026LOGO)

Under the terms of the agreement between Alpharma Ireland Limited and DURECT, Alpharma has paid DURECT an upfront license fee of $20 million, with possible additional payments of up to $93 million upon the achievement of predefined development and regulatory milestones spread over multiple clinical indications and geographical territories as well as possible additional payments of up to $150 million in sales based milestones. If ELADUR is commercialized, DURECT would also receive a royalty on product sales. Alpharma will control and fund the development program.

"We're pleased to be working on the development and commercialization of this product candidate with a team at Alpharma that has been very creative and aggressive in building a leading pain franchise," stated James E. Brown, President and CEO of DURECT.

ELADUR is an investigational transdermal d
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
4. Genmab Reaches Milestone in Ofatumumab Collaboration
5. Titan Spine Teams Up With Syndicom, Inc. to Utilize Internationally Recognized SpineConnect Collaboration Platform
6. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
7. Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
8. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
9. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
10. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
11. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...E, Gabon, December 2 , - ...blem and Heritage" , Coinciding with the ...the,Gabonese Republic is hosting an international ...afeguarding biological resources in Africa. The,co...leaders, ministers,scientific experts, private co...
(Date:12/2/2009)...E, Mass., Dec. 2 TechConnect World...logy development and product integration in cleant...ember 11th deadline for technology abstracts and b... TechConnect World, in association with the Nano S...ean Technology and Sustainable Industries Organiza...
(Date:12/2/2009)...E, Dec. 2 S*BIO Pte Ltd today anno...hibitor, SB1518, at The American Society of Hemato...eans. ,, Data will be presented on the clinical... SB1518 detailing its safety, tolerability and pha...se levels ranging from 100 to 600 mg. These doses ...
(Date:12/2/2009)..., China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharm...: SCR ), a leading pharmaceutical company,specia...eting of branded,generic and proprietary pharmaceu...rugs have been included in China,s National Drug R...ina,s Ministry of Human Resources and Social,Secur...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
...eneCopoeia announces the launch of a suite of miRN...lude 1) miExpress(TM) vector based precursor miRNA...equence (3, UTR) expression clones; and 3) All-in-...a lentiviral vector system, miExpress(TM) precurs...nown miRNAs for human (750), mouse (450), and rat ...
...scheduled for March 12, 2009 , , NEW YORK, March... ) today announced that it received a letter from ...at the Company had failed to regain compliance wit...es the Company to have a minimum of $2,500,000 in ...of listed securities, or $500,000 of net income fr...
...eoGenomics, Inc. (NASD OTC Bulletin Board: NGNM), ...ng laboratories, today announced its results for t... 2008. , , Fourth Quarter 2008 Highlights: ...ase of 56% year-over-year from Q4 07 , 17.... 08 , Avg. Rev/Requisition increased 13.7%...
Other Biology Technology:GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 3Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 4NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 2NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 3NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 4NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 5NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 6NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 7NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 8
(Date:12/3/2009)..., Preliminary Press Conference Topics, Last Cal...ces museum, Attention PIOs: Sending Press Releas...ration deadline 10 December, News Media registra...pre-registration deadline THIS MONDAY, 7 December,...regarding visas for international reporters, pleas...
(Date:12/3/2009)...by a social snubbing? Your genetics, not your frie...wn that opium-like painkillers, called opioids, re...of emotional stress. Now, a new study reviewed by ... that small genetic differences in the gene for th...eople,s responses to social rejection. , In the...
(Date:12/3/2009)...tic snowmelt that occurred during the 2008-09 aust...itive phases for two main climate drivers, ENSO (E...misphere Annular Mode), according to Dr. Marco Ted...ciences at The City College of New York. , Pro...y at the CUNY Graduate Center, added that Antarcti...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6CCNY professor foresees rising Antarctic snowmelt 2UCF Athletes Set Example While Getting Protected Against Flu 58583 1UCF Athletes Set Example While Getting Protected Against Flu 58583 2Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 1Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 2Private Care Association of Floridas Elects Jim Mark as Vice President 58579 1Private Care Association of Floridas Elects Jim Mark as Vice President 58579 2
...n University] Leading academics and practitioners... latest advances in bioengineering research and na... from ink jets and a new, injectable method for re... Brown University April 4-6, 2008. , It is the fi...t Bioengineering Conference, which will take place...
...rean delivery for their first child go on to have ...aditional way. This is shown in a study from the N...versity of Bergen. , Researchers at the NIPHs Med...ave collected data on all first-time births from 1...vers nearly 600 000 births, so the results are sta...
...er to saving the Earth from global warming lie in ...le University aims to design soils that can remove...effectively. This has never previously been attemp...unded by the Engineering and Physical Sciences Res...iative exploits the fact that plants, crops and tr...
Other Biology News:Brown hosts regional bioengineering conference 2Fewer babies born after Caesarean delivery 2Specially-designed soils could help combat climate change 2
Cell Proliferation Kit from GE Healthcare, formerly Amersham Biosciences
Goat Anti-Human Dysadherin 2 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Goat Anti-Human Bcl-2, phospho (Thr74) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Trx-2 Monoclonal Antibody, Unconjugated, Clone 71G4 from Santa Cruz Biotechnology, Inc.
Biology Products: